The use of cimetropii bromidum as premedication for endoscopy of the upper gastro-intestinal tract: a double-blind controlled clinical trial.

The effectiveness of cimetropii bromidum (10 or 20 mg i.v.) as premedication for upper gastro-intestinal tract endoscopy was examined and compared with that of placebo in a double-blind crossover study involving 160 patients. The drug effects were assessed from the degree of opening of the pyloric sphincter and the endoscopist's rating of drug performance. The study showed that the effects of cimetropii bromidum differed highly significantly (p less than 0.0001) from those of placebo, on either count. No adverse effects were noted.

RCT Entities:   Population Interventions Outcomes